secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-05-27T23:59:59+00:00
Accession:  0000950170-22-010855
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

KalVista director Daniel Soland resigns; Patrick Treanor appointed to board
---------------------------------------------------------------------------

- Daniel Soland resigned from board and committees effective May 25, 2022; not due to any disagreement with the Company.
- Patrick Treanor appointed as Class II director effective May 26, 2022, term expiring at 2024 annual meeting.
- Treanor to receive initial option for 17,000 shares, $42,500 annual cash retainer, and annual option for 10,000 shares after one year.
- Treanor determined independent under NASDAQ rules; will execute standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/0000950170-22-010855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/kalv-20220525.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer